The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...
LA JOLLA, Calif., July 30, 2025--(BUSINESS WIRE)--AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory ...
The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...
Eighteen RCTs with a total of 6086 patients were included in the analysis. For patients with moderate to severe chronic obstructive pulmonary disease (COPD), dual bronchodilator therapy with a ...
LA JOLLA, Calif., October 07, 2025--(BUSINESS WIRE)--AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic ...
GlaxoSmithKline's experimental once-daily lung drug LAMA/LABA showed positive results on Monday from late stage trials in patients with chronic obstructive pulmonary disease (COPD). The Phase III data ...
It’s also applying it to “a range” of inhaled cocktail therapies in its pipeline, including a fixed-dose triple combo of LAMA/LABA/inhaled corticosteroid. - read the release The top 15 pharma ...
AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results